C-RAD has installed its first Catalyst System for respiratory gating together with the Elekta Response 2 Interface in Europe.
C-RAD has been selected as the preferred supplier of Elekta for Free Breathing Gating based on optical surface tracking. The interface to Elekta Gating has been implemented in the Catalyst System. The first setup of this combination in Europe was installed at the University Hospital in Kuopio Finland. C-RAD performed successfully the tests of their implementation of the Elekta Gating interface.
The next step is the joint validation. The necessary items are planned and will be performed in close cooperation between C-RAD and Elekta. After the successful validation Catalyst and Sentinel will be listed in the Elekta price book.
Respiratory gated treatments based on free breathing are frequently used when the target volume is close to cardiac tissue or for special treatments in which tumor position depends on the respiratory cycle. The Catalyst and Sentinel system offer the required technology to perform such high end treatment techniques within radiation therapy. With this solution C-RAD supports the whole 4D treatment chain from imaging to delivery.
Jan Seppala, Physicist at Kuopio University Hospital
“Kuopio University Hospital Cancer Center is happy to collaborate with C-RAD on the verification and validation of gating interface on an Elekta linac. Our Cancer Center is looking forward for the clinical implementation and achievement of the complete gating solution.”
Tim Thurn, CEO, C-RAD AB:
“C-RAD appreciates the very good cooperation and support with the University Hospital Kuopio. The successful installation was an important milestone for C-RAD towards getting the Elekta gating interface clinically released. We are focusing our resources on the last outstanding steps of the joined validation.”
C-RAD develops new and innovative solutions for the use in advanced radiation therapy. The company group of C-RAD offers products and solutions for patient positioning, tumor localization and radiation treatment systems. End users are radiation therapy clinics worldwide. All product development is conducted in three fully owned subsidiaries; C-RAD Positioning AB, C-RAD Imaging AB and C-RAD Innovation AB. C-RAD Imaging AB is located in Östersund while the other companies are located in Uppsala. Numbers of employees are currently 24 people. The activities in C-RAD AB originate from research and development at the Karolinska Institutet in Solna. Sales of the company’s first product, the C-RAD SentinelTM, started in 2007. Cooperation agreements have been signed with the Swedish company Elekta, the US company Varian and the Belgian company IBA. C-RAD is represented by distributors specialized in radiation therapy on major markets. C-RAD has founded three companies for direct sales, C-RAD Incorporated in the US, C-RAD GmbH in Germany and C-RAD WOFE in China. C-RAD has acquired 29 % of the laser company Cyrpa and with an option to acquire the remaining 71 %. C-RAD AB is since March 2010 listed at Nasdaq Omx First North Premier.
For more information on C-RAD, please visit www.c-rad.com.
For further information:
Tim Thurn, CEO C-RAD AB, Phone +46-18-666931, E-mail email@example.com
C-Rad AB Logo